TIL

Instil Bio, Inc.

10.62 USD
+0.29 (+2.81%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Instil Bio, Inc. stock is down -7.65% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 June’s closed higher than May.

About Instil Bio, Inc.

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL) Product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, and cervical cancer.